1.
JAMA Oncol
; 10(3): 405-407, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38270961
RESUMO
This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.
